Project Grant HT94252410262
- Grant Award Summary The University of Melbourne received a $1.12 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded April 1, 2026, with a completion date of March 31, 2029. The grant funds research focused on developing novel biological therapies to target a tumor-specific isoform of HER2 (human epidermal growth factor receptor 2) for the treatment of advanced breast cancer. This three-year research...
- This federal Project Grant award in the amount of $733,068.00 was issued by the Defense Health Agency to the University of Melbourne on September 1, 2023 under the Military Medical Research and Development program (CFDA 12.420). The funding will support a 3-year research project titled "Investigating Transcript Diversity as a Driver of Melanoma Progression and Recurrence." The University of Melbourne will conduct basic, translational, and clinical research aimed at developing new...
- The University of Melbourne was awarded a $591,778 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to conduct research aimed at "Harnessing the Immune Response in Exceptionally Long-Term Survivors to Develop Novel Therapeutics." The project will run from May 1, 2024 to April 30, 2027. The University of Melbourne has a history of conducting federal research and consulting work in areas such as...
- This $1,072,784 federal Project Grant was awarded on May 1, 2024 by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to the University of Melbourne (Australia) to conduct research aimed at "IMPROVING OVARIAN CANCER OUTCOMES BY UNDERSTANDING AND TARGETING ACQUIRED RESISTANCE." The research project is scheduled for completion on April 30, 2028. The University of Melbourne has a history of successfully delivering...
- The Department of the Army Medical Command awarded $608,341 to Monash University under the Military Medical Research and Development federal grant program (CFDA 12.420) from September 15, 2022 through September 14, 2025. The project grant funding will support Monash University's research efforts to elucidate and suppress cells of origin of cutaneous melanoma. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical...
- This Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is funding the University of Melbourne to conduct research aimed at addressing a major complication of Parkinson's disease - debilitating constipation. The $968,717 award, spanning April 2025 to April 2028, will support the development of novel pharmacological interventions to target this issue. The University of Melbourne, a prominent international...
- The Defense Health Agency awarded a $744,997 Project Grant to the University of Queensland in Australia under the Military Medical Research and Development program (CFDA 12.420). This grant, titled "DISCOVERING THERAPEUTIC VULNERABILITIES OF CIRCULATING MELANOMA CLUSTERS," provides funding for the university to conduct cutting-edge biomedical research on melanoma from June 1, 2024 through May 31, 2027. The University of Queensland, a leading research institution in Australia, has an...
- The University of Melbourne received a $389,161 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support research on "The Linkage of Neuroendocrine, Neurovascular, and Metabolic Factors in ME/CFS". The award period runs from February 1, 2025 to January 31, 2027. The University of Melbourne, a prominent international academic institution in Australia, will conduct advanced biomedical research to investigate...
- Federal Project Grant Award Summary The University of Melbourne received a $721,656 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective November 1, 2025, through October 31, 2028. This award funds research on minimally-invasive measurement of pressure dynamics in the brain following traumatic brain injury (TBI). The research will be conducted at the University of Melbourne's facility in Australia and represents...
- The University of Queensland in Australia was awarded a $744,744 USD project grant from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project titled "Understanding the Role of Immature Myeloid Cells in Early Melanoma Establishment" from September 30, 2022 to September 29, 2025. Through this funding, researchers at The University of Queensland will investigate the role of immature myeloid...
The Defense Health Agency awarded a $4,319,388 Project Grant to the University of Melbourne to fund research aimed at "TARGETING SENESCENT CELLS TO IMPROVE OUTCOMES FOR BREAST CANCER PATIENTS" over the period from September 1, 2024 to August 31, 2028. This grant is provided under the Military Medical Research and Development Program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The University of Melbourne has a history of conducting federal grant-funded research in areas such as cancer, neurological disorders, and traumatic injuries. Past grant collaborators have included institutions like Washington University in St. Louis and St. Jude Children's Research Hospital.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $4.3m | 3/25/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
TA109486WEHIS | The Walter And Eliza Hall Institute Of Medical Research | Project Grant HT94252410262 | $331.1k | 6/17/25 |